Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?

Slides:



Advertisements
Similar presentations
Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.
Advertisements

Giancarlo Agnelli Università di Perugia Anticoagulant treatment for PE: optimal duration.
Stacey Graven, ACNP Vascular Surgery, Springfield Clinic Springfield, Illinois.
Treatment of Acute Pulmonary Embolism
Chapter Six Venous Disease Coalition Acute Management of VTE VTE Toolkit.
VTE in abdominal-pelvic surgery patients
Results: 1.Progression of thrombus length and volume (40% vs. 28%; P
Long-Term Outcome After Additional Catheter-Directed Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis (The CaVenT Study):
Joint Hospital Surgical Grand Round
Prophylaxis of Venous Thromboembolism
Venous thromboembolism –
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.
Risk of VTE – when is anticoagulation required treatment of VTE – what is optimum anticoagulant survival advantage with heparins new anticoagulants – how.
DVT Prophylaxis in Medical Patients Rog Kyle, MD MUSC 6/5/12.
QUICK DESIGN GUIDE (--THIS SECTION DOES NOT PRINT--) This PowerPoint 2007 template produces a 36”x60” professional poster. It will save you valuable time.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
Venous thromboembolism: how long to treat?
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
DVT Prophylaxis in Orthopedic Patients Rogers Kyle, MD Medical University of South Carolina 11/27/12.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
DVT Prophylaxis in Orthopedic Patients Rogers Kyle 11/27/12.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Postoperative venous thromboembolic disease prevention in the neurosurgery population Ahmad Khaldi, M.D. 1 Michael Wall, PharmD 2 T.C. Origitano, M.D.,
Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,
Venous Thromboembolism
Cancer-Associated Thrombosis
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,
MANAGEMENT OF POST-ENDOVENOUS ABLATION VENOUS THROMBOSIS Stephen F. Daugherty, MD, FACS Clarksville, Tennessee, USA.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
ST CATHERINE’S HOSPICE The management of venous thromboembolism when the evidence is lacking M Johnson.
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.
Preceptor : Dr. Suraj Speaker : Dr. Manik. Annual incidence of venous thromboembolism is approximately 0.1 percent, 0.01 percent in early adulthood.
DVT & PE: How early can I mobilize a patient ??
Acute Venous Pulmonary Embolism Restore cardiopulmonary hemodynamics Avoid recurrence Avoid chronic thromboembolic pulmonary hypertension Restore cardiopulmonary.
Prophylaxis Diagnosis Treatment Venous Thromboembolism Management.
Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.
Ambulatory Venous Hypertension Components Obstruction Valve incompetence Obstruction Valve incompetence Obstruction and valve incompetence …Highest venous.
Case 2: IVC Filters 44 y/o male “preaching pastor” 10/23Generalized seizure Large AVM 2/12Embolization, left frontal craniotomy and resection c/b right.
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.
Venous Thromboembolism (VTE) Prophylaxis at Cesarean Section Phillip N. Rauk, MD.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Outpatient DVT assessment & treatment Daniel Gilada.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Current Standards for Treatment of DVT
Postoperative Calf Venous Thrombosis: Location, Location, Location
Venous Thromboembolism Prophylaxis for Medical Inpatients
Clinical Professor in Palliative Medicine
Deep Venous Thrombosis Anthony J. Comerota, MD, FACS, FACC
By: Dr. Nalaka Gunawansa
APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.
Fig. 2. Comparative efficacy of thromboprophylaxis interventions in the prevention of deep vein thrombosis (DVT). (A) Estimated odds ratios (ORs) and 95%
Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon
Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y
New Oral Anticoagulants and VTE Management
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Succinct Review of the New VTE Prevention and Management Guidelines
A meta-analysis of anticoagulation for calf deep venous thrombosis
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Presentation transcript:

Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?

Acute DVT Management What is the goal of therapy?

Reduce CVI Acute DVT Therapeutic Goals/Options No Rx Caval Filter Anticoagulation Thrombolytic Rx Thrombectomy Reduce PE X X X X X X X X Prevent Extension X X X X + + Reduce Recurrence X X X X + + Restore Patency X X X X Preserve Valve Function X X X X X X X X + +

Langerstedt CI, et al. Lancet Isolated Calf DVT 51 patients randomized Rx 51 patients randomized Rx Heparin x 5 days Warfarin x 3 mos Heparin x 5 days Warfarin x 3 mos No recurrent VTE 29% recurrent VTE 19% proximal DVT 4% pulmonary emboli

Initial treatment –Importance of therapeutic levels –Compression –Ambulation Long-term treatment –5 patient categories Initial treatment –Importance of therapeutic levels –Compression –Ambulation Long-term treatment –5 patient categories TreatmentTreatment Deep Vein Thrombosis

Acute DVT Importance of Early Rx Recurrent VTE* Hull, RD et al NEJM 1990 Hull, RD et al NEJM 1990 * most occur > 4 weeks association with poor initial response not appreciated by attending MDs * most occur > 4 weeks association with poor initial response not appreciated by attending MDs PTT <1.5x (24 hrs.) PTT >1.5x 24.5% (15:1) < %

Heparin/LMWH Bioavailability Heparin for Acute DVT Bratt G, et al. Thromb Rea 1986;42(5): Bara L, et al. Thromb Res. 1985;39(5): Bratt G, et al. Thromb Rea 1986;42(5): Bara L, et al. Thromb Res. 1985;39(5): Plasma Recovery Plasma Level After SQ - Volunteers Single Subcutaneous Injection Unfractionated heparin (UFH) LMWH 20% 90%

Prospective Adjusted dose unfractionated heparin Fixed dose SQ LMWH Objective outcome measures Symptomatic recurrent DVT Change in thrombus size Major bleeding Mortality Prospective Adjusted dose unfractionated heparin Fixed dose SQ LMWH Objective outcome measures Symptomatic recurrent DVT Change in thrombus size Major bleeding Mortality LMWH vs. UFH for Acute DVT A Meta-Analysis of 10 Studies (n=759) Bratt G, et al. Thromb Rea 1986;42(5): Bara L, et al. Thromb Res. 1985;39(5): Bratt G, et al. Thromb Rea 1986;42(5): Bara L, et al. Thromb Res. 1985;39(5):

LMWH vs. UFH for Acute DVT A Meta-Analysis of 10 Studies (n=759) Lensing AWA, et al Arch Intern Med 1995 Lensing AWA, et al Arch Intern Med 1995 Venographic Change 6.5% 3.1% 53% <0.01 Improved 52% 63% - - Worse 12% 6% <0.001 Major Bleed 2.8% 0.8% 68% <0.005 Mortality 7.1% 3.9% 47% <0.04 UFH LMWH Risk Reduction Risk Reduction P-value

Proximal DVT- 53 patients LMWH...then randomize: –Bed rest –Ambulation + 35 mm Hg stocking –Ambulation + 50 mm Hg compression bandage Activity measured - pedometer Venous duplex days 0 & 9 Proximal DVT- 53 patients LMWH...then randomize: –Bed rest –Ambulation + 35 mm Hg stocking –Ambulation + 50 mm Hg compression bandage Activity measured - pedometer Venous duplex days 0 & 9 Deep Vein Thrombosis Initial Treatment: Compression & Ambulation 1.Blattler W., et al Int’l Angiol. 2003; 32: Partsch H. et al J Vasc Surg 2000; 32: Blattler W., et al Int’l Angiol. 2003; 32: Partsch H. et al J Vasc Surg 2000; 32: 861-9